Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

It's important to look beyond the headlines and find out more about how effective coronavirus vaccine candidates are.

What Data This Coronavirus Expert Is Looking For In Pfizer and Moderna's Vaccine Trials

BioNTech SE

Surface Oncology Inc

These three stocks are loaded with potential, but need to be watched carefully over the next few weeks.

3 Top Biotech Stocks to Watch in November

AstraZeneca

Johnson & Johnson

Novavax

Should You Buy a Basket of Late-Stage Coronavirus Vaccine Stocks?

Takeda Pharmaceutical

The numbers are close, but two players stand out at the moment.

Which Coronavirus Vaccine Maker Is Poised to Be the Top Supplier?

The best way to pick coronavirus stocks is to make sure you trust the scientists running the company's COVID-19 program.

How To Invest In COVID-19 Vaccine Stocks: Bet On The Jockey

The biotech -- and its shareholders -- should be ready for various possible scenarios.

What if Moderna Doesn't Win the Coronavirus Vaccine Race?

Getting FDA authorization for a COVID-19 vaccine may be just the first hurdle of many.

Coronavirus Vaccine Stocks: Challenges With Manufacturing, Distribution, And the Cold Chain

Data on mRNA-1273, one of the top potential coronavirus vaccines, will be reviewed by the National Institutes of Health.

Moderna Finishes Initial Data Collection in Coronavirus Vaccine Trial; Results Could Be Published Soon

Here are pharmaceutical stocks for November 2020 with a focus on companies that are close to delivering a vaccine against Covid-19. The post 3 Pharmaceutical Stocks to Buy in November appeared first on InvestorPlace.

3 Pharmaceutical Stocks to Buy in November

Moderna (MRNA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Moderna (MRNA) Surges: Stock Moves 6.5% Higher

Swiss drugs regulator Swissmedic said on Friday it has begun a rolling review of a COVID-19 vaccine candidate from U.S.-based Moderna , which is currently analyzing data from a large-scale clinical trial in thousands of patients.

Swiss start rolling review of Moderna COVID-19 vaccine candidate

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Swissmedic begins rolling review of Moderna's mRNA vaccine against COVID-19 (mRNA-1273).

Swissmedic Begins Rolling Review of Moderna's mRNA Vaccine Against COVID-19 (mRNA-1273)

Nikola

Snowflake

Tesla

Wayfair

Workhorse Group

Zoom Video

There are periods when a handful of holdings can become overvalued stocks to sell. Here are seven potential names to watch.

7 Overvalued Stocks to Drop Before They Drop You

The stock price of Moderna Inc (NASDAQ: MRNA) has received a price target increase from $80 to $88 by Argus. These are the details.

MRNA Stock Price: $88 Target By Argus

Moderna is expected to release crucial data in coming days from a late-stage trial that will show whether its coronavirus vaccine is effective.

Crucial Moderna Covid vaccine data is coming in days – here's what to look out for

A late Wednesday announcement from Moderna Inc (NASDAQ: MRNA) signaled that the biopharma is still locked in a neck-to-neck race with Pfizer Inc. (NYSE: PFE) to develop a coronavirus vaccine. What Happened: The number of COVID-19 cases required to conduct the pre-planned first interim analysis of Phase 3 data has accrued, the Cambridge, Massachusetts-based company said.

Moderna Achieves COVID-19 Case Number For First Interim Readout: What's Next?

News from Moderna regarding an excellent update from its novel coronavirus vaccine trial has MRNA stock rising on Thursday morning. The post MRNA Stock: Moderna Shares Surge on Covid-19 Vaccine Update appeared first on InvestorPlace.

MRNA Stock: Moderna Shares Surge on Covid-19 Vaccine Update

Moderna ((MRNA) is set for the first interim analysis of its late-stage coronavirus vaccine study. Positive data may support an emergency use authorization by the end of 2020.

Moderna (MRNA) Up on Coronavirus Vaccine Candidate Progress

After all the news surrounding a possible COVID-19 vaccine this week, it's no surprise that the former frontrunner Moderna Inc (NASDAQ:MRNA) chimed in this morning with an update on their candidate.

Options Traders Flock to Moderna Stock After Vaccine Update

Moderna (MRNA) will soon release initial clinical results of its Phase 3 vaccine candidate.

Moderna (MRNA) Up 20% After Pfizer (PFE) News

Moderna's stock price jumped early Thursday as the biotech firm drew one step closer to revealing how well its experimental coronavirus vaccine works.

Moderna stock jumps after key step toward COVID-19 vaccine results

It's bitter-sweet. More people are becoming infected with coronavirus so vaccine trial results are being released quicker. The race for an effective vaccine is heating up, with Moderna signaling late on Wednesday it is readying data from its current COVID-19 vaccine trial.  US drugmaker Pfizer was first, reporting on Monday that its coronavirus vaccine is 90% effective in trials, and its smaller rival Moderna isn't far behind. Moderna's Phase 3 'COVE' trial is testing its vaccine candidate, mRNA-1273, a vaccine that uses a similar technology to Pfizer's BNT162b2. On Wednesday, Moderna said it has hit 'trigger point' for submitting its interim trial data to an independent safety board. This means it could likely release the results of its trial as early as this month, intensifying the race among pharma companies around the world to be the first to land an effective vaccine against COVID-19.

Fauci predicts good results from Moderna's COVID-19 vaccine trial because it's similar to Pfizer's, but warns against declaring victory

Fauci described the vaccines by Pfizer and Moderna as a “major step not only for Covid-19 but for the entire field of vaccinology.”

Fauci Predicts Further Covid-19 Vaccine Success As Moderna Prepares To Submit Early Findings

Shares in Moderna jumped as much as 5% in pre-market trading on Thursday after Anthony Fauci, the US's leading infectious-disease expert, said he was optimistic about the company's upcoming COVID-19 vaccine trial data.  The US drugmaker said on Wednesday that it has enough cases to begin the first interim analysis of its COVID-19 vaccine, called mRNA-1273.

Moderna jumps 5% after Fauci says its upcoming COVID-19 vaccine trial data may be positive

Moderna, Inc. (MRNA) CEO Stéphane Bancel Presents at Credit Suisse 29th Annual Virtual Healthcare Conference (Transcript)

News for Moderna Stock (MRNA)